RECRUITING

A Study of GNTI-122 in Adults Recently Diagnosed With T1D

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood cells in adult participants with recently diagnosed T1D. After assessment of eligibility, participants who qualify for the study will be enrolled sequentially in 1 of 3 cohorts. Cohort 1 participants (n=3) receive a low dose of GNTI-122 . Cohort 2 participants (n=3) receive a high dose of GNTI-122. Cohort 3 participants (n=10) receive a high dose of GNTI-122 in combination with rapamycin. Participants are followed for 78 weeks after the administration of GNTI-122 during which safety and efficacy assessments are made, including vital signs, ECG, physical exam, clinical labs, and monitoring of adverse events and concomitant medications. Disease markers (e.g., MMTT-stimulated C-peptide, HbA1c) and pharmacodynamic activity (e.g., lymphocyte subsets and phenotypes, effector T cell responses to islet antigens ex vivo, T1D autoantibodies) will be monitored serially throughout the study. The study will include sentinel dosing and a Safety Review Committee to ensure participant safety.

Official Title

POLARIS: A Phase 1, Single Dose, Open-label Study of GNTI-122 in Adults With Recently Diagnosed Type 1 Diabetes (T1D)

Quick Facts

Study Start:2025-09-03
Study Completion:2028-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06919354

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Male and female participants aged ≥18 to ≤45 years with recently diagnosed (within 120 days of Screening) T1D according to American Diabetes Association criteria.
  2. 2. Participant has residual β-cell function during Screening, defined as random C-peptide ≥ 0.2 nmol/L.
  3. 3. Positive for at least one T1D-associated autoantibody.
  4. 4. Able and willing to provide written, informed consent as approved by the IRB.
  5. 5. Requires and is on insulin therapy.
  6. 6. Is confirmed positive for the HLA-DRB1\*04:01 allele.
  7. 7. Has adequate vascular access to undergo leukapheresis with no known contraindications.
  8. 8. Female participants of childbearing potential must have a negative serum pregnancy test at Screening, must be not lactating, and must agree to protocol-specified contraception.
  9. 9. Male participants of childbearing potential must agree to protocol specified contraception.
  10. 10. Other than T1D, participant is in good general health.
  1. 1. Type 2 diabetes.
  2. 2. Experienced DKA within 4 weeks prior to or during Screening.
  3. 3. Unwilling or unable to comply with study procedures or schedule.
  4. 4. Chronic or uncontrolled medical condition.
  5. 5. Has another active or autoimmune or inflammatory disease with the exception of well-controlled Hashimoto's thyroiditis, celiac disease, or vitiligo.
  6. 6. Participation in another clinical study or active follow-up in a prior study.

Contacts and Locations

Study Contact

Kristin M Neff
CONTACT
857-327-5483
clinical_ops@GentiBio.com

Principal Investigator

Mark Bach, MD
STUDY_DIRECTOR
GentiBio, Inc

Study Locations (Sites)

City of Hope Medical Center
Duarte, California, 91010
United States
University of California - San Diego
San Diego, California, 92093-0990
United States
University of California - San Francisco
San Francisco, California, 94158
United States
University of Florida - Gainesville
Gainesville, Florida, 32610
United States
University of Miami, Diabetes Research Institute
Miami, Florida, 33136
United States
Joslin Diabetes Center
Boston, Massachusetts, 02215
United States
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514
United States
Duke University
Durham, North Carolina, 27710
United States

Collaborators and Investigators

Sponsor: GentiBio, Inc

  • Mark Bach, MD, STUDY_DIRECTOR, GentiBio, Inc

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-09-03
Study Completion Date2028-02

Study Record Updates

Study Start Date2025-09-03
Study Completion Date2028-02

Terms related to this study

Additional Relevant MeSH Terms

  • Type 1 Diabetes (T1D)
  • Type 1 Diabetes Mellitus